Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Inventory: 2021-2025

Historic Inventory for Apellis Pharmaceuticals (APLS) over the last 5 years, with Sep 2025 value amounting to $122.8 million.

  • Apellis Pharmaceuticals' Inventory rose 1.45% to $122.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $122.8 million, marking a year-over-year increase of 1.45%. This contributed to the annual value of $81.4 million for FY2024, which is 44.38% down from last year.
  • Latest data reveals that Apellis Pharmaceuticals reported Inventory of $122.8 million as of Q3 2025, which was up 1.50% from $121.0 million recorded in Q2 2025.
  • Apellis Pharmaceuticals' Inventory's 5-year high stood at $161.3 million during Q1 2024, with a 5-year trough of $1.7 million in Q3 2021.
  • Over the past 3 years, Apellis Pharmaceuticals' median Inventory value was $121.0 million (recorded in 2025), while the average stood at $116.0 million.
  • Per our database at Business Quant, Apellis Pharmaceuticals' Inventory soared by 3,463.09% in 2022 and then plummeted by 48.87% in 2025.
  • Over the past 5 years, Apellis Pharmaceuticals' Inventory (Quarterly) stood at $16.3 million in 2021, then surged by 426.30% to $85.7 million in 2022, then spiked by 70.76% to $146.4 million in 2023, then slumped by 44.38% to $81.4 million in 2024, then rose by 1.45% to $122.8 million in 2025.
  • Its Inventory was $122.8 million in Q3 2025, compared to $121.0 million in Q2 2025 and $82.5 million in Q1 2025.